SGMT
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ: SGMT · HEALTHCARE · BIOTECHNOLOGY
$7.71
+0.92% today
Updated 2026-05-08
Market cap
$476.11M
P/E ratio
—
P/S ratio
52.50x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$3 – $11
Volume
1.6M
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $2.00M | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | -100.0% | — |
| Cost of revenue | $88000.00 | $124000.00 | $134000.00 | $130000.00 | — | — | — |
| Gross profit | $-88000.00 | $-124000.00 | $-134000.00 | $-130000.00 | $2.00M | — | — |
| Gross margin | — | — | — | — | 100.0% | — | — |
| R&D | $8.39M | $8.18M | $19.34M | $24.92M | $19.78M | $38.44M | $39.05M |
| SG&A | $5.86M | $3.22M | $4.38M | $6.14M | $12.96M | $16.01M | $17.84M |
| Operating income | $-14.16M | $-11.40M | $-23.72M | $-31.05M | $-30.74M | $-54.45M | $-56.89M |
| Operating margin | — | — | — | — | -1537.0% | — | — |
| EBITDA | $-14.11M | $-11.40M | $-23.72M | $-31.05M | $-30.74M | $-45.57M | $-56.89M |
| EBITDA margin | — | — | — | — | -1537.0% | — | — |
| EBIT | $-14.20M | $-11.40M | $-23.72M | $-31.05M | $-61.48M | $-54.45M | — |
| Interest expense | $64000.00 | $0.00 | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.26M | $-11.37M | $-24.44M | $-30.50M | $-27.88M | $-45.57M | $-51.04M |
| Net income growth (YoY) | — | +20.3% | -115.0% | -24.8% | +8.6% | -63.5% | -12.0% |
| Profit margin | — | — | — | — | -1393.8% | — | — |